Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal

Aimmune Therapeutics, which this year won the first FDA approval for a food allergy immunotherapy, is set to be acquired by a division of global food giant Nestlé in a deal that values the biopharmaceutical company at $2.6 billion.

According to deal terms announced Monday, Nestlé will pay $34.50 for each Aimmune share that it doesn’t already own. The offer represents a more than 173 percent premium to Aimmune’s closing stock price on Friday, but it’s just 14 percent higher than Aimmune’s stock price in February, after it won FDA approval for its peanut allergy immunotherapy. Shares sank to a 52-week... Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

          

          

            
Author: Frank Vinluan

Source : https://xconomy.com/san-francisco/2020/08/31/nestle-to-swallow-up-peanut-allergy-drug-maker-aimmune-in-2-6b-deal/

Date : 2020-08-31T13:56:12.000Z